Suppr超能文献

与替诺福韦艾拉酚胺的抗逆转录病毒治疗的 HIV 感染患者中哌拉西林/他唑巴坦相关的严重急性低钾血症:病例报告及文献复习。

Severe acute hypokalaemia associated with piperacillin/tazobactam in an HIV-infected patient under antiretroviral therapy with tenofovir alafenamide: case report and literature review.

机构信息

Department of Medical Education, Taipei Veterans General Hospital, 201 Shih-Pai Road, Sec. 2, Taipei 11247, Taiwan; and School of Medicine, National Yang Ming University, 155 Linong Street, Sec. 2, Taipei 11221, Taiwan.

Department of Medical Education, Taipei Veterans General Hospital, 201 Shih-Pai Road, Sec. 2, Taipei 11247, Taiwan.

出版信息

Sex Health. 2020 Apr;17(2):194-197. doi: 10.1071/SH19069.

Abstract

Piperacillin/tazobactam is a commonly prescribed antimicrobial agent. Tenofovir alafenamide (TAF) is increasingly being used in antiretroviral therapy (ART) of HIV. Herein we report a case of a 57-year-old male with AIDS receiving TAF-containing ART in whom severe refractory hypokalaemia developed after coadministration of piperacillin/tazobactam for suspected hospital-acquired infection. Upon withdrawal of piperacillin/tazobactam, serum potassium concentrations returned to normal within 2 days. Hypokalaemia is a rare adverse effect of piperacillin/tazobactam and may be aggravated with the underlying use of TAF. We also reviewed past reported cases of hypokalaemia after piperacillin/tazobactam administration. We want to highlight that a more cautious approach should be considered when combining piperacillin/tazobactam and TAF in clinical practice.

摘要

哌拉西林/他唑巴坦是一种常用的抗菌药物。替诺福韦艾拉酚胺(TAF)在抗逆转录病毒疗法(ART)中越来越多地用于治疗 HIV。本文报告了一例 57 岁男性 AIDS 患者,在接受含 TAF 的 ART 治疗的同时,因疑似医院获得性感染而合用哌拉西林/他唑巴坦,之后出现严重难治性低钾血症。停用哌拉西林/他唑巴坦后,血清钾浓度在 2 天内恢复正常。低钾血症是哌拉西林/他唑巴坦的罕见不良反应,并且可能因潜在的 TAF 应用而加重。我们还回顾了过去报道的哌拉西林/他唑巴坦给药后低钾血症的病例。我们想强调,在临床实践中,当联合使用哌拉西林/他唑巴坦和 TAF 时,应考虑更谨慎的方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验